News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genome Canada Appoints New Chair of the Board


7/6/2009 10:53:06 AM

OTTAWA, ONTARIO--(Marketwire - July 02, 2009) - Genome Canada is pleased to announce the appointment of Dr. C. Thomas Caskey as Chair of the Board of Directors, effective June 18, 2009.

Dr. Caskey has been a member of Genome Canada's Board of Directors for a number of years and has served in various capacities on a number of committees. He was appointed Vice-Chair in 2008. Dr. Caskey currently serves as Director and Chief Executive Officer of the Brown Foundation Institute of Molecular Medicine, a research institute that seeks to investigate the cause of human diseases at the cellular and molecular levels using DNA and protein technologies to elucidate disease mechanisms. He is also professor at The Institute of Molecular Medicine, University of Texas Health Sciences Center, in Houston. Previously, he was the Managing Director of Cogene Biotech Ventures, venture capital funds designed to support early-stage biotechnology and life sciences companies. He has also served as Chairman of the Department of Molecular & Human Genetics at Baylor College of Medicine. He was Senior Vice President, Human Genetics and Vaccines Discovery at Merck Research Laboratories and President of the Merck Genome Research Institute.

Dr. Caskey is an internist and a prominent medical geneticist and biomedical entrepreneur. Dr. Caskey has received numerous academic and industry-related honors for his work in human genetics. He is a member of the National Academy of Sciences and Institute of Medicine.

Dr. Caskey earned his medical doctorate from Duke University and his undergraduate degree from the University of South Carolina. He is Board certified in Internal Medicine, Clinical Genetics, Metabolic Diseases, and Molecular Diagnostics.

"Dr. Caskey is a distinguished scientist with a highly respected record of accomplishment in his research field, as well as success in his private-sector enterprises, said Dr. Martin Godbout, President and CEO of Genome Canada. Dr. Caskey's appointment comes at an important time for Genome Canada and his qualities as a leader, an innovator and a true champion for genomics and proteomics research will serve us well".

GENOME CANADA

Genome Canada is a not-for-profit Corporation that acts as the primary funding and information resource relating to genomics and proteomics in Canada. Its main objective is to position Canada as a world leader in genomics and proteomics research. Dedicated to developing and implementing a national strategy in genomics and proteomics research for the benefit of all Canadians, it has received $840 million in funding from the Government of Canada since 2000 to which has been added close to $1.0 billion in partnered co-funding and interest earnings.


Contacts:
Genome Canada
Helene Meilleur
Director of Communications and Events
Cell.: 514.258-7629


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES